| P50 | author | Kunle Odunsi | Q38296739 |
| P2093 | author name string | Kevin H Eng | |
| | Brandon-Luke L Seagle | |
| | Monica Dandapani | |
| | Judy Y Yeh | |
| | Shohreh Shahabi | |
| P2860 | cites work | TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance | Q42458495 |
| | TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. | Q44964668 |
| | Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients | Q59616903 |
| | p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation | Q73311464 |
| | Comprehensive molecular portraits of human breast tumours | Q24630844 |
| | MolProbity: all-atom structure validation for macromolecular crystallography | Q24649111 |
| | Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations | Q27730815 |
| | The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer | Q27824864 |
| | Integrated genomic analyses of ovarian carcinoma | Q27860518 |
| | SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling | Q27860614 |
| | The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 |
| | Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal | Q28288215 |
| | Mutational landscape and significance across 12 major cancer types | Q28300353 |
| | Supervised risk predictor of breast cancer based on intrinsic subtypes | Q29617404 |
| | Poor survival with wild-type TP53 ovarian cancer? | Q33761535 |
| | PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. | Q34433549 |
| | TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. | Q34775855 |
| | Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma | Q34965421 |
| | The consequence of oncomorphic TP53 mutations in ovarian cancer | Q37225303 |
| | Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations. | Q37605827 |
| | Mutant p53 in cancer: new functions and therapeutic opportunities | Q38197826 |
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 18641-18652 | |
| P577 | publication date | 2015-06-22 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers | |
| P478 | volume | 6 | |